Krystal BiotechFRA:4KB +2.29%58 Quick Ratio is 9.06 as of Mar. 2026, which is 49% below its 10-year median of 17.80. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Krystal Biotech ranks better than 75.71% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Krystal Biotech's quick ratio for the quarter that ended in Mar. 2026 was 9.06.
Krystal Biotech has a quick ratio of 9.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Krystal Biotech's Quick Ratio or its related term are showing as below:
FRA:4KB'
s Quick Ratio Range Over the Past 10 Years
Min: 6.73 Med: 17.8 Max: 105.46
Current: 9.06
During the past 10 years, Krystal Biotech's highest Quick Ratio was 105.46. The lowest was 6.73. And the median was 17.80.
FRA:4KB's Quick Ratio is ranked better than 75.71% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:4KB: 9.06
Krystal Biotech (FRA:4KB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Krystal Biotech Quick Ratio Related Terms
Krystal Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Quick Ratio Comparison
For the Biotechnology subindustry, Krystal Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Krystal Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a Quick Ratio of 9.06 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Krystal Biotech and its competitors. This is 49% below median its historical median of 17.80. Over the past decade, Krystal Biotech's Quick Ratio has ranged from 6.73 to 105.46. According to the industry distribution chart, Krystal Biotech ranks #344 out of 1416 companies in the Biotechnology industry, placing it in the top 24.3%.
Is Krystal Biotech's Quick Ratio too high?
Krystal Biotech's current Quick Ratio of 9.06 is 49% below median its 10-year median of 17.80. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 105.46. The Biotechnology industry median Quick Ratio is 3.60. Krystal Biotech's value of 9.06 is 151.7% above this industry median. Based on the distribution chart, Krystal Biotech ranks #344 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Quick Ratio compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #344 out of 1416 companies for Quick Ratio. This places Krystal Biotech in the top 24% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Krystal Biotech's value of 9.06 is 151.7% above this benchmark. Historically, Krystal Biotech's own Quick Ratio has ranged from 6.73 to 105.46 over the past decade. While the company's 10-year median is 17.80 vs. the industry median of 3.60, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Quick Ratio of 9.06 is 151.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Quick Ratio is 9.06, which is 49% below median its own 10-year median of 17.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current Quick Ratio is 9.06, which is 49% below median its 10-year median of 17.80 and 151.7% above the Biotechnology industry median of 3.60. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Quick Ratio is 9.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Quick Ratio: 9.06 (49% below median its 10-year median of 17.80)
GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
Industry Position: 151.7% above the Biotechnology median (#344 of 1416)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
